Literature DB >> 16238700

Seizures in HIV/AIDS: a southern African perspective.

A I Bhigjee1.   

Abstract

South Africa, with a population of 44.8 million, has over 5 million human immunodeficiency virus (HIV)-infected individuals. Over 70% of HIV-infected patients will present with clinically relevant neurologic disease at some stage during the course of their disease. New onset seizures occur in 3-11% of these patients. The mechanism of seizure production in HIV-positive patients includes incidental association, HIV itself, opportunistic infections (OIs), neoplasia, cerebrovascular disease, drug toxicity, and metabolic derangements. In developing countries, OIs constitute the largest group presenting with seizures. Seizure management in HIV-positive patients presents special problems, especially with respect to drug-disease and drug-drug interactions. The older antiepileptic drugs (AEDs) are protein-bound and largely depend on the cytochrome p450 system for their metabolism. The newer AEDs may be safer in patients on antiretroviral drugs. However, they are expensive, an important consideration in developing countries.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16238700     DOI: 10.1111/j.1600-0404.2005.00500.x

Source DB:  PubMed          Journal:  Acta Neurol Scand Suppl        ISSN: 0065-1427


  2 in total

1.  Late diagnosis of human immunodeficiency virus infection is linked to higher rates of epilepsy in children in the Eastern Cape of South Africa.

Authors:  Isabel A Michaelis; Maryke Nielsen; Craig Carty; Markus Wolff; Caroline A Sabin; John S Lambert
Journal:  South Afr J HIV Med       Date:  2020-06-30       Impact factor: 2.744

2.  Exposure to multiple parasites is associated with the prevalence of active convulsive epilepsy in sub-Saharan Africa.

Authors:  Gathoni Kamuyu; Christian Bottomley; James Mageto; Brett Lowe; Patricia P Wilkins; John C Noh; Thomas B Nutman; Anthony K Ngugi; Rachael Odhiambo; Ryan G Wagner; Angelina Kakooza-Mwesige; Seth Owusu-Agyei; Kenneth Ae-Ngibise; Honorati Masanja; Faith H A Osier; Peter Odermatt; Charles R Newton
Journal:  PLoS Negl Trop Dis       Date:  2014-05-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.